Vanda Pharmaceuticals (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Sells 156,235 Shares

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos sold 156,235 shares of Vanda Pharmaceuticals stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $8.17, for a total value of $1,276,439.95. Following the completion of the sale, the chief executive officer directly owned 2,704,496 shares of the company’s stock, valued at $22,095,732.32. This trade represents a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA opened at $8.20 on Thursday. Vanda Pharmaceuticals Inc. has a 1-year low of $3.81 and a 1-year high of $9.60. The business has a 50-day moving average price of $7.56 and a two-hundred day moving average price of $5.97. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $484.70 million, a P/E ratio of -2.20 and a beta of 0.55.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The business had revenue of $57.22 million during the quarter, compared to analyst estimates of $59.28 million. Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. Equities analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in VNDA. Vanguard Group Inc. increased its holdings in Vanda Pharmaceuticals by 0.4% during the third quarter. Vanguard Group Inc. now owns 3,587,139 shares of the biopharmaceutical company’s stock worth $17,900,000 after buying an additional 14,336 shares during the last quarter. Millennium Management LLC increased its position in Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after buying an additional 1,470,898 shares during the last quarter. AIGH Capital Management LLC bought a new stake in Vanda Pharmaceuticals in the fourth quarter valued at approximately $17,626,000. Geode Capital Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 4.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,691,638 shares of the biopharmaceutical company’s stock worth $7,986,000 after acquiring an additional 77,997 shares during the last quarter. Finally, Krensavage Asset Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 15.2% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock worth $5,890,000 after acquiring an additional 155,505 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on VNDA. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. Zacks Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. Jefferies Financial Group raised their price target on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a research report on Wednesday, December 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.90.

Vanda Pharmaceuticals News Roundup

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA grants a formal evidentiary public hearing to review CDER’s proposed refusal to approve Vanda’s sNDA for HETLIOZ in jet lag disorder — a rare, potentially company‑moving procedural win that gives Vanda a public forum to challenge the refusal and could materially change approval odds. Vanda Announces FDA Grants Landmark Hearing for HETLIOZ
• Positive Sentiment: HC Wainwright published quarterly EPS forecasts for 2027 and reiterated a Buy rating with a $24 price target — a bullish analyst stance that implies significant upside vs. the current share price and may support investor interest. HC Wainwright issues estimates, Buy $24 PT
• Negative Sentiment: Multiple senior executives sold sizable blocks of stock on/around March 2 — including CEO Mihael H. Polymeropoulos (156,235 shares at ~$8.17, ~$1.28M), CFO Kevin Moran (42,442 shares at ~$8.27), SVPs and the CMO (each sold ~30k–42k shares) — collectively roughly $2.6M of disclosed insider sales and single‑digit percentage reductions in their holdings. Large, coordinated insider sales typically create near‑term selling pressure and can be perceived negatively by investors. Vanda’s Top Brass Quietly Unload a Wave of Shares
• Negative Sentiment: SEC filings disclose the individual insider trades (CEO filing available) — confirms the transactions and provides exact sizes/prices for investor review. These formal filings make the sales official and may reinforce negative market reaction while investors digest motives (tax planning, diversification, or signal). SEC filing — CEO ownership disclosure

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.